MS/Neuroimmunology

Clinical Research


fact_group

If you think you may qualify for one of these studies, please contact Neurology Research Partners at (303) 724-4644 or NeurologyResearchPartners@ucdenver.edu for more information.

 

COMIRB #Title (Please click on the title to see approved advertisement)Principal InvestigatorEligibility and InformationAdvertisement
12-0968Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological DisordersAlvarez, Enrique, MDClinical TrialsN/A
18-1633Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)Alvarez, Enrique, MDClinical TrialsN/A
15-2388Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (DISCO-MS)Corboy, John R., MDClinical TrialsSee Advertisement
17-1884Risk Factors in Early Multiple Sclerosis (RISE-MS)Corboy, John R., MDClinical TrialsSee Advertisement
08-0613The role of TH40 cell in Multiple Sclerosis and Type 1 DiabetesCorboy, John R., MDN/AN/A
09-0952Rocky Mountain MS Center Tissue BankCorboy, John R., MDClinical TrialsN/A
18-0179Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of DeliveryJeffrey Hebert, PT, PhDClinical TrialsSee Advertisement
16-0156Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple SclerosisSchreiner, Teri L., MD, MPHClinical TrialsN/A
12-1102Pediatric Multiple Sclerosis and other Demyelinating Diseases Database (PeMSDD Database)Schreiner, Teri L., MD, MPHN/AN/A
19-1040A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Ocrelizumab Administration in Patients with Multiple SclerosisPiquet, Amanda, MDClinical TrialsN/A
19-2525Lipoic acid for Treatment of Progressive Multiple SclerosisGross, Robert, MDClinical TrialsN/A